N/A N=100 Prescription Digital Therapeutic for the Treatment of Insomnia
Insomnia Chronic
Primary: Change in Insomnia Severity
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=89 The DECIDE Parent-Provider Intervention
Modified DECIDE Intervention · Treatment as Usual Care Group
Primary: Change in Parent Needs & Resources Domain of CANS - Provider Arm Only — 0 units on a scale — p=0.125
N/A N=138 Better Research Interactions for Every Family
Respect · Trust · Study Enrollment
Primary: Study Enrollment Rates — 13; 24; 20; 32 Participants
N/A N=13 EEG Changes With Guided Online Meditation
Meditation
Primary: Number of Participants With EEGs to Measure Changes in Wave Oscillations — 3; 4 Participants with Evaluable EEGs
Phase 4 N=194 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
Virus Diseases
Primary: Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 11 — 100; 100; 99.0 Percentage of participants
N/A N=31 Improving Self-Care of Behavioral Variant Frontotemporal Dementia Caregivers
Behavioral Variant of Frontotemporal Dementia · Caregiver Stress Syndrome
Primary: Change From Baseline in the Self-Care Inventory (SCI) — 71.4; 66.4; 80.4; 68.9 score on a scale
Phase 2 N=117 Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Relapsed Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 82 Participants
Phase 2 N=25 A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Subcutaneous Fat
Primary: Number of Treatment Emergent Adverse Events — 103; 57; 69; 61 number of events
Phase 4 N=62 Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
Schizophrenia
Primary: PANSS Negative Symptom Score — 21.5; 23 units on a scale — p=0.36
N/A N=350 Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon
Peripheral Arterial Disease · Peripheral Vascular Diseases · Arterial Occlusive Diseases
Primary: Number of Participants That Achieve Optimal PTA Results — 254 Participants
N/A N=2,701 COVID-19 Vaccination Take-Up
Covid19 · Vaccination
Primary: Rate of COVID-19 Vaccination at 1 Month — 12; 4; 0; 1 Participants
N/A N=90 The Effects of Mixed Working Memory Training on Subsequent Training Gains Among Older Adults
Cognitive Aging
Primary: Change in Overall Working Memory — 0.42; 0.26; -0.01; 0.04 Standard unit change — p=0.355
Phase 1 N=53 AMG 334 20160172 Pediatric Migraine PK Study.
Migraine
Primary: Time to Maximum Concentration (Tmax) of Erenumab — 7.0; 7.0; 9.0; 7.0 days
N/A N=281 Increasing Help-Seeking Behavior Among Transitioning Veterans at Risk for Suicide With Online Gatekeeper Training
Suicide Prevention
Primary: Recruitment — 281; 997 Participants
N/A N=200 Clinical Evaluation of the CM-1500 in Postoperative Surgery Patients
Blood Loss
Primary: Relative Index Change During PACU Stay — -2.01; -1.32 Relative Index (RI)